UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Cross-immunogenicity: antibodies to infliximab in Remicade-treated patients with IBD similarly recognise the biosimilar Remsima

Gut, 2016-07, Vol.65 (7), p.1132-1138

2016

Volltextzugriff (PDF)

S619 Immune-Based Personalized Elimination Diet for the Treatment of Irritable Bowel Syndrome: A Double-Blind Randomized Sham-Controlled Study

The American journal of gastroenterology, 2023-10, Vol.118 (10S), p.S454-S455

2023

Volltextzugriff (PDF)

Molecular Landscape of Anti-Drug Antibodies Reveals the Mechanism of the Immune Response Following Treatment With TNFα Antagonists

Frontiers in immunology, 2019-12, Vol.10, p.2921-2921

2019

Volltextzugriff (PDF)

Delaying an infliximab infusion by more than 3 days is associated with a significant reduction in trough levels but not with clinical worsening

Therapeutic advances in gastroenterology, 2022-03, Vol.15, p.17562848221083395-17562848221083395

2022

Volltextzugriff (PDF)

Infliximab levels and antibodies in IBD-related peripheral arthralgia

International journal of colorectal disease, 2020-06, Vol.35 (6), p.1141-1148

2020

Volltextzugriff (PDF)

Characterization of blood-derived exosomal hTERT mRNA as a biomarker for colon cancer and Lynch syndrome

Frontiers in oncology, 2022-09, Vol.12, p.962473-962473

2022

Volltextzugriff (PDF)

Acute Chest Pain as an Infusion Reaction to Vedolizumab

Case reports in gastroenterology, 2022-05, Vol.16 (2), p.430-434

2022

Volltextzugriff (PDF)

Do Vedolizumab trough Levels Predict the Outcome of Subsequent Therapy in Inflammatory Bowel Disease?

Biomedicines, 2023-05, Vol.11 (6), p.1553

2023

Volltextzugriff (PDF)

Adalimumab Level in Breast Milk of a Nursing Mother

Clinical gastroenterology and hepatology, 2010-05, Vol.8 (5), p.475-476

2010

Volltextzugriff (PDF)

Serum Syndecan-1: A Novel Biomarker for Pancreatic Ductal Adenocarcinoma

Clinical and translational gastroenterology, 2022-05, Vol.13 (5), p.e00473-e00473

2022

Volltextzugriff (PDF)

Serum MMP-9: a novel biomarker for prediction of clinical relapse in patients with quiescent Crohn’s disease, a post hoc analysis

Therapeutic advances in gastroenterology, 2019, Vol.12, p.1756284819881590-1756284819881590

2019

Volltextzugriff (PDF)

Significance of low level infliximab in the absence of anti-infliximab antibodies

World journal of gastroenterology : WJG, 2015-02, Vol.21 (6), p.1907-1914

2015

Volltextzugriff (PDF)

The temporal evolution of antidrug antibodies in patients with inflammatory bowel disease treated with infliximab

Gut, 2014-08, Vol.63 (8), p.1258-1264

2014

Volltextzugriff (PDF)

Optimizing Anti-TNF-α Therapy: Serum Levels of Infliximab and Adalimumab Are Associated With Mucosal Healing in Patients With Inflammatory Bowel Diseases

Clinical gastroenterology and hepatology, 2016-04, Vol.14 (4), p.550-557.e2

2016

Volltextzugriff (PDF)

Association of Vedolizumab Level, Anti-Drug Antibodies, and α4β7 Occupancy With Response in Patients With Inflammatory Bowel Diseases

Clinical gastroenterology and hepatology, 2018-05, Vol.16 (5), p.697-705.e7

2018

Volltextzugriff (PDF)

The immunogenic part of infliximab is the F(ab′)2, but measuring antibodies to the intact infliximab molecule is more clinically useful

Gut, 2011-01, Vol.60 (1), p.41-48

2011

Volltextzugriff (PDF)

Prospective Observational Evaluation of Time-Dependency of Adalimumab Immunogenicity and Drug Concentrations: The POETIC Study

The American journal of gastroenterology, 2018-06, Vol.113 (6), p.890-898

2018

Volltextzugriff (PDF)

Clinical utility of antihuman lambda chain‐based enzyme‐linked immunosorbent assay (ELISA) versus double antigen ELISA for the detection of anti‐infliximab antibodies

Inflammatory bowel diseases, 2012-09, Vol.18 (9), p.1628-1633

2012

Volltextzugriff (PDF)

Serum matrix metalloproteinase-7: a potential biomarker in patients with Lynch Syndrome

Molecular biology reports, 2023-09, Vol.50 (9), p.7471-7477

2023

Volltextzugriff (PDF)

Host transcriptome signatures in human faecal-washes predict histological remission in patients with IBD

Gut, 2022-10, Vol.71 (10), p.1988-1997

2022

Volltextzugriff (PDF)

The Association Between Drug Levels and Endoscopic Recurrence in Postoperative Patients with Crohn's Disease Treated with Tumor Necrosis Factor Inhibitors

Inflammatory bowel diseases, 2017-11, Vol.23 (11), p.1924-1929

2017

Volltextzugriff (PDF)

Association Between Infliximab Drug and Antibody Levels and Therapy Outcome in Pediatric Inflammatory Bowel Diseases

Journal of pediatric gastroenterology and nutrition, 2018-10, Vol.67 (4), p.507-512

2018

Volltextzugriff (PDF)

Propagation of EBV-driven Lymphomatous Transformation of Peripheral Blood B Cells by Immunomodulators and Biologics Used in the Treatment of Inflammatory Bowel Disease

Inflammatory bowel diseases, 2020-09, Vol.26 (9), p.1330-1339

2020

Volltextzugriff (PDF)

Detection of infliximab in breast milk of nursing mothers with inflammatory bowel disease

Journal of Crohn's and colitis, 2011-12, Vol.5 (6), p.555-558

2011

Volltextzugriff (PDF)

Sa1708 - The Effect of IBD Biologic Drugs on Lymphomatous Transformation of EBV-Infected Peripheral Blood Mononuclear Cells

Gastroenterology (New York, N.Y. 1943), 2018-05, Vol.154 (6), p.S-364-S-364

2018

Volltextzugriff (PDF)

1 – 25 von 54

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(52)
Mit Volltextzugriff
(51)

Publikationsform

Artikel
(53)
Berichte
(1)

Sprache

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(35)
Science & Technology
(35)
Gastroenterology & Hepatology
(26)
Humans
(24)
Adult
(16)
Inflammatory Bowel Disease
(15)
Female
(14)
Male
(12)
Inflammatory Bowel Diseases - Drug Therapy
(11)
Infliximab
(10)
Crohn Disease - Drug Therapy
(8)
Middle Aged
(8)
Patients
(8)
Young Adult
(8)
Antibodies, Monoclonal - Therapeutic Use
(7)
Ibd
(7)
Adalimumab
(6)
Antibodies, Monoclonal - Immunology
(6)
Gastroenterology And Hepatology
(6)
Immunology
(6)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Cross-immunogenicity: antibodies to infliximab in Remicade-treated patients with IBD similarly recognise the biosimilar Remsima

S619 Immune-Based Personalized Elimination Diet for the Treatment of Irritable Bowel Syndrome: A Double-Blind Randomized Sham-Controlled Study

Molecular Landscape of Anti-Drug Antibodies Reveals the Mechanism of the Immune Response Following Treatment With TNFα Antagonists

Delaying an infliximab infusion by more than 3 days is associated with a significant reduction in trough levels but not with clinical worsening

Infliximab levels and antibodies in IBD-related peripheral arthralgia

Characterization of blood-derived exosomal hTERT mRNA as a biomarker for colon cancer and Lynch syndrome

Acute Chest Pain as an Infusion Reaction to Vedolizumab

Do Vedolizumab trough Levels Predict the Outcome of Subsequent Therapy in Inflammatory Bowel Disease?

Adalimumab Level in Breast Milk of a Nursing Mother

Serum Syndecan-1: A Novel Biomarker for Pancreatic Ductal Adenocarcinoma

Serum MMP-9: a novel biomarker for prediction of clinical relapse in patients with quiescent Crohn’s disease, a post hoc analysis

Significance of low level infliximab in the absence of anti-infliximab antibodies

The temporal evolution of antidrug antibodies in patients with inflammatory bowel disease treated with infliximab

Optimizing Anti-TNF-α Therapy: Serum Levels of Infliximab and Adalimumab Are Associated With Mucosal Healing in Patients With Inflammatory Bowel Diseases

Association of Vedolizumab Level, Anti-Drug Antibodies, and α4β7 Occupancy With Response in Patients With Inflammatory Bowel Diseases

The immunogenic part of infliximab is the F(ab′)2, but measuring antibodies to the intact infliximab molecule is more clinically useful

Prospective Observational Evaluation of Time-Dependency of Adalimumab Immunogenicity and Drug Concentrations: The POETIC Study

Clinical utility of antihuman lambda chain‐based enzyme‐linked immunosorbent assay (ELISA) versus double antigen ELISA for the detection of anti‐infliximab antibodies

Serum matrix metalloproteinase-7: a potential biomarker in patients with Lynch Syndrome

Host transcriptome signatures in human faecal-washes predict histological remission in patients with IBD

The Association Between Drug Levels and Endoscopic Recurrence in Postoperative Patients with Crohn's Disease Treated with Tumor Necrosis Factor Inhibitors

Association Between Infliximab Drug and Antibody Levels and Therapy Outcome in Pediatric Inflammatory Bowel Diseases

Propagation of EBV-driven Lymphomatous Transformation of Peripheral Blood B Cells by Immunomodulators and Biologics Used in the Treatment of Inflammatory Bowel Disease

Detection of infliximab in breast milk of nursing mothers with inflammatory bowel disease

Sa1708 - The Effect of IBD Biologic Drugs on Lymphomatous Transformation of EBV-Infected Peripheral Blood Mononuclear Cells

Suchergebnisse filtern